Overview

Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder

Status:
Completed

Trial end date:
2003-07-01

Target enrollment:
0

Participant gender:
All

Summary

Biochemotherapy (combined immunotherapeutic drugs and chemotherapeutic drugs) has shown virtue than that use chemical or biological drugs alone in the treatment of some malignant tumor. Here we investigated the efficacy of sequential intravesical therapy with EPI and BCG to EPI or BCG alone in patients with transitional cell carcinoma of bladder cancer after surgical management.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

LanZhou University

Treatments:

Epirubicin

Criteria

Inclusion Criteria:

- primary single or multiple (more than 2 tumors) pTa to pT1 transitional cell
carcinoma, solitary or multiple grade Ⅲ tumors and primary or concomitant carcinoma in
situ of the bladder were included in the study

Exclusion Criteria:

- Previous radiotherapy, intravesicial or systemic chemotherapy within 3 months of the
study, presence of a second primary malignancy and transitional cell carcinoma of the
upper urinary tract or prostatic urethra, invasion of periurethral prostatic ducts,
prostatic gland or stroma were exclusion criteria